Hot Integrated Utility Stocks To Buy Right Now

SAN FRANCISCO (MarketWatch) ��Among the shares expected to see active trade in Wednesday�� session are those of Macy�� Inc., Deere & Co. and Cisco Systems Inc.

Macy�� (M) �is projected to report first-quarter earnings of 59 cents a share, according to a consensus survey by FactSet. Expectations for the first quarter are subdued due to weather disruptions, with investors likely to focus their attention on details for April and May, analyst Charles Grom at Sterne Agee said in a note.

Bloomberg Enlarge Image

Deere (DE) �is forecast to post second-quarter earnings of $2.47 a share.

10 Best Construction Stocks To Watch Right Now: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:

• [By gurujx]

  Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

  The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.

Hot Integrated Utility Stocks To Buy Right Now: Colonial Municipal Income Trust (CMU)

MFS High Yield Municipal Trust operates as a nondiversified, closed-end management investment company. The trust invests primarily in medium and lower quality bonds and notes issued by or on behalf of state and local government units. Its portfolio primarily comprises investments in health care, tax-backed, utilities, transportation, housing, education, industrials, resource recovery, industrial, manufacturing, oil and gas, and refunded/escrowed sectors. Columbia Management Advisors, Inc. serves as the investment advisor of the trust. The trust was formerly known as Colonial Municipal Income Trust and changed its name to MFS High Yield Municipal Trust in 2007. MFS High Yield Municipal Trust was founded in 1987 and is based in Boston, Massachusetts.

Advisors' Opinion:

• [By Paul McWilliams]

  Marvell (MRVL) is clearly carrying a big zit on its forehead from the ongoing legal battle with Carnigie Mellon University (CMU). A jury awarded CMU damages slightly in excess of $1B, and the judge could triple that.

Hot Integrated Utility Stocks To Buy Right Now: Chelsea Therapeutics International Ltd.(CHTP)

Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure and falls related to NOH in Parkinson?s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, adult attention deficit hyperactivity disorder, chronic fatigue syndrome, and freezing of gait in PD and down syndrome. The company intends to market its Droxidopa drug under the Northera brand name. It also engages in developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn?s disease, ankylosing spondylitis, uveitis, psoriatic arthritis, inflammatory bowel disease, cancer, and other immunological disorders. The company?s molecule products include a portfolio of metabolically inert antifolate molecules consisting of CH-1504 and CH-4051, which are orally available molecules with anti-inflammatory, autoimmune, and anti-tumor properties that inhibit various key enzymes required for cell proliferation; and a portfolio of dihydroorotate dehydrogenase, known as the I-3D portfolio, for applications in autoimmune diseases and transplantation. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.

Advisors' Opinion:

• [By Roberto Pedone]

  Chelsea Therapeutics (CHTP)
  is a specialty pharmaceutical company focused on acquisition, development and commercialization of pharmaceutical products for the treatment of a variety of human diseases. This stock closed up 9% to $2.89 in Thursday's trading session.

  Thursday's Range: $2.55-$2.98
  
  52-Week Range: $0.73-$3.25
  
  Thursday's Volume: 1.74 million
  
  Three-Month Average Volume: 1.14 million

  From a technical perspective, CHTP ripped sharply higher here right off its 50-day moving average of $2.55 with above-average volume. This stock has been uptrending strong for the last two months, with shares moving higher from its low of $1.78 t its recent high of $3.25. During that move, shares of CHTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CHTP within range of triggering a major breakout trade. That trade will hit if CHTP manages to take out some near-term overhead resistance levels at $3 to its 52-week high at $3.25 with high volume.

  Traders should now look for long-biased trades in CHTP as long as it's trending above its 50-day at $2.55 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.14 million shares. If that breakout triggers soon, then CHTP will set up to enter new 52-week-high territory above $3.25, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $4.21 to $4.40.

• [By Bryan Murphy]

  What do Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), National Bank of Greece (NYSE:NBG), and Walter Energy, Inc. (NYSE:WLT) have in common. They all have charts worth a much closer look right now. That's not to say they're all dropping the same bullish hint. In fact, WLT, NBG, and CHTP are all dropping distinctly-different hints as to their likely near-term future. But, trading action is trading action no matter which direction it's in. Take a look.
  
  Yes: Truth be told, shares of the National Bank of Greece have been working on a rally for a while. It's only been recently, however, that NBG has made it clear it's not going to give up. The stock crossed above the 100-day moving average line (gray) early in the month, and has continued to peel away. Yes, National Bank of Greece hit something of a soft patch last week, but the 20-day moving average line (blue) has since stepped up to the plate as a technical floor, rekindling the uptrend yesterday day and today. Perhaps most bullish of all is the fact that NBG has started to increase volume on the way up, after it cleared the 100-day moving average line,

Hot Integrated Utility Stocks To Buy Right Now: TTM Technologies Inc.(TTMI)

TTM Technologies, Inc., together with its subsidiaries, provides printed circuit board (PCB) products and backplane assemblies worldwide. Its PCB products include conventional, high density interconnect, flexible, and rigid-flex PCBs, as well as backplane assemblies and IC substrates. The company also offers various services, such as design for manufacturability support during new product introduction stages, PCB layout design, simulation and testing services, quick turnaround production, and drilling and routing services. Its customers include original equipment manufacturers and electronic manufacturing service companies that primarily serve the networking/communications, aerospace/defense, high-end computing, cell phone, and medical/industrial/instrumentation end markets of the electronics industry. TTM Technologies, Inc. was founded in 1978 and is headquartered in Santa Ana, California.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of printed circuit board specialist TTM Technologies (NASDAQ: TTMI  ) soared 17% today after its quarterly results topped Wall Street expectations.